Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tazobactam

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    91 result(s) found for: Tazobactam. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2016-000398-19 Sponsor Protocol Number: AGO/2016/002 Start Date*: 2016-03-08
    Sponsor Name:Ghent University
    Full Title: Pilot study: pharmacokinetics of beta-lactam antibiotics, piperacillin-tazobactam, ceftazidim and meropenem in blood and sputum of cystic fibrosis patients.
    Medical condition: Cystic fibrosis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005131-15 Sponsor Protocol Number: 2008/0828 Start Date*: 2008-12-19
    Sponsor Name:CHRU de Lille
    Full Title: ETUDE DE LA PHARMACOCINETIQUE DE L’ASSOCIATION PIPERACILLINE – TAZOBACTAM EN UTILISATION INTRA-VEINEUSE CONTINUE CHEZ L’ENFANT NEUTROPENIQUE FEBRILE .
    Medical condition: febrile episodes in neutropenic patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053223 Febrile aplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003374-40 Sponsor Protocol Number: 1-2016 Start Date*: 2016-11-29
    Sponsor Name:University of Tartu
    Full Title: The effects of augmented renal clearance on the pharmacokinetic/pharmacodynamic profile of piperacillin/tazobactam in children and young adults with malignant or non-malignant haematological or onc...
    Medical condition: The state of renal hyperfiltration during infection in children and young adults with malignant or non-malignant haematological or oncological diagnosis
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002644-14 Sponsor Protocol Number: Start Date*: 2015-09-15
    Sponsor Name:Alder Hey Children's NHS Foundation Trust
    Full Title: POPPET Study - Pharmacokinetics of continuous administration of Piperacillin/Tazobactam to children using an elastomeric pump
    Medical condition: Febrile Neutropenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-003485-24 Sponsor Protocol Number: CXA-PEDS-13-08 Start Date*: 2014-09-25
    Sponsor Name:Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 1, Non-comparative, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Ceftolozane/tazobactam in Pediatric Patients Receiving Standard of Care Antibiotic ...
    Medical condition: This study is designed to assess the PK, safety, and tolerability of a single intravenous dose of ceftolozane/tazobactam in pediatric patients.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10018657 Gram-negative bacterial infection NOS LLT
    20.0 100000004865 10049086 Antibacterial prophylaxis LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021369-66 Sponsor Protocol Number: UMM062010FS Start Date*: 2010-11-16
    Sponsor Name:Department of Pharmacy Universitaetsmedizin Mainz
    Full Title: Investigation of pharmacokinetics of Ciprofloxacin and Piperacillin/Tazobactam in Patients receiving continuous renal replacement therapy
    Medical condition: Sepsis and acute renal failure (ARF) are two pathological entities that commonly co-exist in patients admitted to intensive care. Antibiotic dosing in septic patients with ARF can be complicated a...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000059-42 Sponsor Protocol Number: 31/17/0334 Start Date*: 2018-07-25
    Sponsor Name:CHU DE TOULOUSE
    Full Title: Comparison of short infusion versus prolonged infusion of ceftolozane-tazobactam among patients with ventilator associated-pneumonia to Pseudomonas aeruginosa in intensive care units
    Medical condition: Ventilator associated-pneumonia to Pseudomonas aeruginosa in intensive care units
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004704-19 Sponsor Protocol Number: MK-7625A-036 Start Date*: 2019-08-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: A Phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nos...
    Medical condition: Nosocomial pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) EE (Trial now transitioned) Outside EU/EEA GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021050-20 Sponsor Protocol Number: AGO/2010/003 Start Date*: 2010-08-25
    Sponsor Name:Ghent University Hospital
    Full Title: Assessment of the optimal dosing of piperacillin-tazobactam in intensive care unit patients: extended versus continuous infusion
    Medical condition: Patients admitted on the intensive care unit (surgical and medical surgery)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002388-33 Sponsor Protocol Number: ZKSJ0086 Start Date*: 2016-09-05
    Sponsor Name:Friedrich-Schiller-University Jena
    Full Title: Therapeutic drug monitoring (TDM) for personalized antibiotic treatment with piperacillin-tazobactam (PipTaz) in patients with febrile neutropenia after myelo-suppressive cytostatic chemotherapy
    Medical condition: Patients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactam
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001809-14 Sponsor Protocol Number: E2015-PK-HD-PTAZ-MERO-CTAZ Start Date*: 2015-06-24
    Sponsor Name:Hopital Erasme
    Full Title: Beta-Lactams (ceftazidime, piperacilline-tazobactam, meropenem) dosing scheme validation in septic hemodialysed patient
    Medical condition: sepsis in patient undergoing dialysis for renal insufficiency
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10040054 Sepsis, bacteraemia, viraemia and fungaemia NEC HLT
    18.0 100000004869 10012347 Dependence on renal dialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000955-16 Sponsor Protocol Number: PIPLEVOLUNG Start Date*: 2020-01-28
    Sponsor Name:Medical University of Vienna
    Full Title: Pulmonary pharmacokinetics of piperacillin/tazobactam and levofloxacin in patients with chronic obstructive pulmonary disease or cystic fibrosis: Comparison of epithelial lining fluid, in-vivo micr...
    Medical condition: Pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004470-28 Sponsor Protocol Number: 2011RM010 Start Date*: 2011-10-18
    Sponsor Name:University Hospital of South Manchester
    Full Title: Plasma and intrapulmonary population pharmacokinetics of piperacillin/tazobactam in critically ill patients
    Medical condition: Critical illness, ventilator associated pneumonia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10065153 Ventilator associated pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-002636-31 Sponsor Protocol Number: APHP211034 Start Date*: 2022-09-15
    Sponsor Name:Assistance Publique Hôpitaux de Paris/DRCI
    Full Title: Piperacillin-tazobactam and temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae in the in...
    Medical condition: severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002862-11 Sponsor Protocol Number: CXA-NP-11-04 Start Date*: 2015-07-27
    Sponsor Name:Cubist Pharmaceuticals GmbH
    Full Title: A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated...
    Medical condition: Ventilated Nosocomial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed) DE (Completed) BE (Completed) LV (Completed) CZ (Completed) HU (Completed) SK (Completed) AT (Completed) GR (Completed) PT (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000246-34 Sponsor Protocol Number: 7655A-014 Start Date*: 2015-09-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/T...
    Medical condition: Treatment for hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed) LV (Completed) BG (Completed) PT (Completed) LT (Completed) FR (Completed) ES (Completed) HR (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002278-33 Sponsor Protocol Number: PK_AB_NICU Start Date*: 2018-09-27
    Sponsor Name:Department of Clinical Pharmacology/Medical University of Vienna
    Full Title: Pharmacokinetics of antibiotics in cerebrospinal fluid of children with external ventricular drain
    Medical condition: We will obtain pharmacokinetic data of cefuroxime, vancomycin, gentamicin, ampicillin, linezolid, piperacillin/tazobactam and cefazolin in cerebrospinal fluid and plasma of children with external v...
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003496-36 Sponsor Protocol Number: 69HCL17_0843 Start Date*: 2019-11-06
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Dosage optimization of piperacillin/tazobactam in ICU patients based on therapeutic drug monitoring of amikacin - OPTIMA
    Medical condition: sepsis or septic shock
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    20.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024606-34 Sponsor Protocol Number: 2010-PI-0521 Start Date*: 2011-04-11
    Sponsor Name:Mª Victoria Gil Navarro
    Full Title: Eficacia y seguridad de Piperacilina/Tazobactam administrada en perfusión continua versus infusión intermitente en pacientes con infección complicada o nosocomial con sospecha o aislamiento de Pseu...
    Medical condition: infecciones complicadas o de origen nosocomial con sospecha o aislamiento de Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    13 10021860 Infección por Pseudomonas aeruginosa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-004820-41 Sponsor Protocol Number: MK-7625A-035 Start Date*: 2017-08-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropen...
    Medical condition: Complicated intra-abdominal infection (cIAI)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) HU (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 14:28:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA